Search

Potassium acetate

Agkistrodon piscivorus antivenin

It is intravenously (IV) administered to limit/prevent systemic toxicity [FDA label]. … The cottonmouth, Agkistrodon piscivorus, is a large, venomous snake in the pit viper subfamily (Crotalinae).

Drometrizole trisiloxane

Drometrizole trisiloxane is a photostable UVA and UVB light filter [A33069, L2780, L2781, L2782, L2783, F81]. … The compound is a lipophilic benzotriazole derivative marketed as Meroxyl XL by L'Oreal, although sunscreens with drometrizole trisiloxane are currently only approved for use in the EU, Canada, Australia

Bexarotene

Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.

Potassium perchlorate

The use of potassium perchlorate as a component in sealing gaskets for food containers has been revoked by the FDA following the use being abandoned by the industry [L2365]. … Potassium perchlorate acts as a competitive inhibitor of iodine uptake by the thyroid gland and attenuates the production of the thyroid hormone.

Enalapril

It was developed from a targeted research programmed using molecular modelling. … It is also found in a combination product containing [hydrochlorothiazide] that is used for the management of hypertension.

Fenofibrate

[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993.[L8585] … Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil].[A185954] Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.

Technetium Tc-99m nofetumomab merpentan

[A32115] The NR-LU-10 antibody is directed against a 40 kDa glycoprotein antigen expressed in a variety of cancers and some normal tissues. … [FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14, 1992.

Fosnetupitant

Fosnetupitant is the pro-drug form of netupitant [FDA label]. … Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg

Strontium ranelate

Strontium ranelate, a strontium (II) salt of ranelic acid, is a medication for osteoporosis. … It is therefore promoted as a "dual action bone agent" (DABA) indicated for use in treatment of severe osteoporosis.